Literature DB >> 2882047

The effects of somatostatin and SMS 201-995 on experimentally-induced pancreatitis and endotoxaemia in rats and on monocyte activity in patients with cirrhosis and portal hypertension.

S A Jenkins, J N Baxter, D W Day, A M Al-Sumidaie, S J Leinster, R Shields.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2882047

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  5 in total

1.  Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure.

Authors:  F Fiedler; G Jauernig; V Keim; A Richter; H J Bender
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

2.  A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.

Authors:  C McKay; J Baxter; C Imrie
Journal:  Int J Pancreatol       Date:  1997-02

3.  Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice.

Authors:  Savio G Barreto; Colin J Carati; Ann C Schloithe; James Toouli; Gino T P Saccone
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

Review 4.  Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis.

Authors:  M W Büchler; M Binder; H Friess
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 5.  Somatostatin and somatostatin analogues--are they indicated in the management of acute pancreatitis?

Authors:  C J McKay; C W Imrie; J N Baxter
Journal:  Gut       Date:  1993-11       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.